PT - JOURNAL ARTICLE AU - Emily Littlejohn TI - Hydroxychloroquine use in the COVID-19 patient AID - 10.3949/ccjm.87a.ccc011 DP - 2020 May 05 TA - Cleveland Clinic Journal of Medicine 4099 - http://www.ccjm.org/content/early/2020/06/16/ccjm.87a.ccc011.short 4100 - http://www.ccjm.org/content/early/2020/06/16/ccjm.87a.ccc011.full AB - Hydroxychloroquine (HCQ) has multiple potential antiviral mechanisms of action that differ according to the pathogen studied (eg, Chikungunya, Dengue virus, human immunodeficiency virus, poliovirus, Zika virus). Data on HCQ for treatment of coronavirus disease 2019 (COVID-19) are rapidly evolving. To date, there is no evidence from randomized controlled trials that HCQ, or any single therapy, improves outcomes in patients infected with COVID-19. There are also no clinical trial data supporting prophylactic HCQ therapy in COVID-19. Use of HCQ in patients with COVID-19 is being investigated for prophylaxis, postexposure prophylaxis, and treatment.